OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Subscription & copyright page	317
FBXW10: a male-biased E3 ligase in liver cancer	193
Engineering growth factor ligands and receptors for therapeutic innovation	183
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	180
Spliced to kill: RNA mis-splicing derived cancer neoantigens	171
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	165
Platelets: tailoring metastasis treatment	153
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	150
Revumenib: a new era in acute leukemia treatment	138
Tumor-resident microbes: the new kids on the microenvironment block	137
Advisory Board and Contents	136
Subscription & copyright page	135
Subscription and copyright page	128
Navigating life as an early career researcher	128
Onco-condensates: formation, multi-component organization, and biological functions	127
Engine shutdown: migrastatic strategies and prevention of metastases	124
Accessing the vasculature in cancer: revising an old hallmark	119
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	116
Radiotherapy and immunotherapy: open questions and future strategies	115
Leveraging circulating microbial DNA for early cancer detection	113
Subscription & copyright page	104
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	90
GOT2 consider the tumor microenvironment	81
Advisory Board and Contents	80
Chromatin as an old and new anticancer target	75

Oncogenic competence: balancing mutations, cellular state, and microenvironment	75
Tumor immunology CRISPR screening: present, past, and future	74
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	73
Gut microbiota – a double-edged sword in cancer immunotherapy	73
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	73
Recent developments in myeloid immune modulation in cancer therapy	70
Benefits and opportunities of the transgenic Oncopig cancer model	68
Chromosomal instability and aneuploidy as causes of cancer drug resistance	67
Regulation of metastatic organotropism	65
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	64
Pannexin biology and emerging linkages to cancer	63
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	63
Diet, nutrient supply, and tumor immune responses	63
Crosstalk of T cells within the ovarian cancer microenvironment	62
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	60
Cell death, therapeutics, and the immune response in cancer	60
Subscription & copyright page	57
Advisory Board and Contents	56
Subscription & copyright page	56
Cancer catecholamine conundrum	55
Advisory Board and Contents	55
Genetic immune escape in cancer: timing and implications for treatment	55
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	55
Palmitate paves the way to lung metastasis	52
Scaling data toward pan-cancer foundation models	50
Advisory Board and Contents	49
β-Galactosylceramidase in cancer: friend or foe?	48
Subscription & copyright page	48
Insights on ErbB glycosylation – contributions to precision oncology	47
Inflammation: the incubator of the tumor microenvironment	46
Advisory Board and Contents	45
The emerging field of oncolytic virus-based cancer immunotherapy	45
Advisory Board and Contents	45
Clinical and translational relevance of intratumor heterogeneity	45
Advisory Board and Contents	44
Redefining precision cancer prevention to promote health equity	43
Subscription and copyright page	43
Subscription & copyright page	43
Advisory Board and Contents	43
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	43
Modeling metastasis in mice: a closer look	42
Stress granules and hormetic adaptation of cancer	42
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	41
Advancing cancer precision surgery with the tumor coagulome	41
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	40
B7-H3: a robust target for immunotherapy in prostate cancer	40
Molecular and clinical insights into early-onset endometrial cancer	40
Prospects for understanding and exploiting the consequences of hyperactivation lethality	39
Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges	39
RHOA takes the RHOad less traveled to cancer	39

Circulating cell-free DNA-based multi-cancer early detection	38
Emerging mechanisms of telomerase reactivation in cancer	38
Updating cancer research with patient-focused networks	38
Advisory Board and Contents	37
Advisory Board and Contents	37
Targeting TIM-3 to halt lung precancer progression	36
Advisory Board and Contents	36
Subscription & copyright page	36
Beyond safety: suicide systems in cell-based cancer therapies	35
A macrophage-neutrophil program drives mammary carcinogenesis	35
Immune response and inflammation in cancer health disparities	35
Cross-dressing of dendritic cells strengthens antitumor immunity	35
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	35
A tipping point in cancer epidemiology: embracing a life course exposomic framework	35
Advisory Board and Contents	34
Leveraging space innovations for cancer breakthroughs on Earth	34
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	34
Dissecting liver tumor heterogeneity to improve health equity	34
Functional heterogeneity of fibroblasts in primary tumors and metastases	33
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises	33
Neoantigen-directed therapeutics in the clinic: where are we?	33
Time-of-day dependency of adoptive cell therapies	32
Cancer cell adaptability: turning ribonucleoprotein granules into targets	31
Advisory Board and Contents	31
Subscription & copyright page	31
Advisory Board and Contents	30
Dying to survive: harnessing inflammatory cell death for better immunotherapy	30
Engineered bacterial therapeutics for detecting and treating CRC	30
Space in cancer biology: its role and implications	29
Clonal evolution and hierarchy in myeloid malignancies	29
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	28
Epigenetic basis and targeting of cancer metastasis	28
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	28
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	28
Ferroptosis vulnerability in FLT3-mutant leukemia	28
Addressing the genetic/nongenetic duality in cancer with systems biology	27
Subscription & copyright page	27
Advisory Board and Contents	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	27
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	26
Next-generation immunotherapies for brain metastatic cancers	26
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	26
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	26
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	25
The development of therapy related myeloid neoplasms in childhood cancer survivors	25
NETscape or NEThance: tailoring anti-cancer therapy	25
Genitourinary cancer neoadjuvant therapies: current and future approaches	25
Immunomodulation by endothelial cells: prospects for cancer therapy	24
Overstretched and overlooked: solving challenges faced by early-career investigators after the pandemic	24
Next-generation cancer vaccines and emerging immunotherapy combinations	24
Lifileucel: the first cellular therapy approved for solid tumours	24
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	23
Deciphering the roles of ABCB5 in normal and cancer cells	23
Subscription & copyright page	23
Persisting cancer cells are different from bacterial persisters	22
Future perspectives on engineered T cells for cancer	22
The extracellular matrix in cancer: from understanding to targeting	22
Embracing diversity: macrophage complexity in cancer	22
Successfully targeting the cancer system with metronomics for medulloblastoma	22
How cancer cells make and respond to interferon-I	21
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	21
Tissue architecture in tumor initiation and progression	21
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy	20
Enhancing dendritic cells by inhibiting BCL2	20
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	20
Think zebras: challenges and opportunities for treating rare cancers	20
Defining obesity in the context of cancer: thinking beyond body mass index	20
TET2, tumor control, and CAR T cell hyperproliferation	20
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity	20
Acetylation: a new target for protein degradation in cancer	20
Subscription & copyright page	20